card-3216_Biochemistry expert scientific with eyeglasses
Digital innovation

Driving operational improvements and quality of our services

card-3210_Laboratory technicians conduct a series of tests on a chemical analyzer
Science Innovation

Uniquely positioned to shape, validate, and deliver biomarker assessments that strive to improve patient outcomes across diverse Therapeutic Areas

card-3242_Scientist using tablet while colleagues working behind
Download our Corporate brochure

We are IQVIA Laboratories, a leading clinical trial laboratory services organization with end-to-end laboratory services and secure, enterprise-wide biospecimen and consent management solutions.

Download
card-3233_Laboratory scientist working at lab with micropipette, and 96 well plate
Corporate Video

Our commitment to customer success is embedded in every facet of our operations.

card-3210_Laboratory technicians conduct a series of tests on a chemical analyzer
Science Innovation

Uniquely positioned to shape, validate, and deliver biomarker assessments that strive to improve patient outcomes across diverse Therapeutic Areas

card-3216_Biochemistry expert scientific with eyeglasses
Digital Innovation

Driving operational improvements and quality of our services

English You are about to exit for another IQVIA country or region specific website Please be aware that the website you have requested is intended for the residents of a particular country or region, as noted on that site. Ok Open in new tab Search
hero bg-3255_Female Research Scientist Putting Test Tubes with Blood Samples into Analyzer

Tumor Mutational Burden Analysis

A TMB assay utilizing  a whole exome sequencing (WES) of tumor specimens for reliable quantification of TMB across various tumor indications

Tumor Mutational Burden (TMB) is a putative biomarker of response to checkpoint inhibitor therapy. Our TMB assay is a component of our comprehensive immuno-oncology assay portfolio and is available for RUO or GCP applications.

Highlights:

  • TMB assay available in two formats: tumor-only specimens or matched tumor and germline control blood specimens.
  • Based on validated WES assay targeting ~60Mb of coding region of the human genome.
  • TMB tumor-only WES method modeled across multiple tumor indications.
  • High quantitative precision (CV% ≤20%) for TMB >2, suitable for TMB analysis across a wide range of cancer indications including those with traditionally low TMB.
IQVIA Laboratories
IQVIA Laboratories
TMB (WES)1
1.5
(N=123)
2.4
(N=38)
2.4
(N=100)
4.6
(N=64)
8.7
(N=39)
10.1
(N=258)
13.2
(N=113)
Published TMB2 1.8
(N=220)
2.5
(N=1456)
2.7
(N=543)
4.5
(N=7758)
7.2
(N=80)
9
(N=2102)
14.4
(N=879)

 

1 Median TMB scores generated from TCGA whole exome sequencing reads through our pipeline
2 Median TMB scores per Chalmers et al., Genome Medicine 2017
3 https://gdc.cancer.gov/about-data /publications/mc3-2017
LGG=Lower Grade Glioma, CHOL=Cholangiocarcinoma, KIRC=Renal Clear Cell Carcinoma, COAD=Colon Adenocarcinoma, BLCA=Urothelial Carcinoma, LUSC=Lung Squamous Cell Carcinoma,
SKCM=Cutaneous Melanoma, BRCA=Breast Invasive Carcinoma, HNSC=Head-Neck Squamous Cell Carcinoma, LUAD=Lung Adenocarcinoma, SKCM=Cutaneous Melanoma; STAD=Stomach Adenocarcinoma

 

TMB assay specifications

Sample Types Tumor tissue (FFPE, fresh frozen or DNA specimens) Normal tissue, optional (PBMC, whole blood or DNA
DNA Requirements 250 ng DNA
Assay Method Whole Exome Sequencing
System Compatibility NovaSeq 6000, HiSeq 2500
Assay Performance >99.9% accuracy of variant calling for variants above 10% allelic frequency Quantitative precision ≤20% CV% across TMB range of 2-32
Deliverables TMB score, FASTQ, BAM, annotated VCF files

 

Immuno Assay Portfolio

 

Our TMB assay is a component of our comprehensive immuno-oncology assay portfolio

3234_Liquid drop from pipette to test tube

Related Services

card-3233_Laboratory scientist working at lab with micropipette, and 96 well plate

Clinical Genomics Laboratory Services

Learn more
card-3215_People working at laboratory

Next Generation Sequencing Services

Learn more
card-3270_young woman scientist in laboratory working

Microsatellite Instability (MSI) Assay

Learn more
card-3241_Technician holding blood tube test in the research laboratory

Immune Landscape Signatures

Learn more
card-3223_Nurse standing in a laboratory and taking test tubes with blood samples

TruSight Oncology 500 Plasma Assay

Learn more
card-3233_Laboratory scientist working at lab with micropipette, and 96 well plate

RNA Sequencing and DNA Sequencing Services

Learn more
card-3223_Nurse standing in a laboratory and taking test tubes with blood samples

Biomarker Services

Learn more
card-3235_Pipetting robot laboratory

Bioinformatics

Learn more
card-3275_Young scientist works in modern laboratory

Central Laboratory Services

Learn more

Related Insights

Reproducibility Challenges in an era of Massive Data

Presented at the MCBIOS & MAQC 2021 Joint Conference

A Verified Genomic Reference Sample for Assessing Performance of Cancer Panels Detecting Small Variants of Low Allele Frequency

Presented at the MCBIOS & MAQC 2021 Joint Conference

Unexpected Impacts to Library Complexity After DNA and RNA Library Preparation in Illumina Next Generation Sequencing

Presented at the MCBIOS & MAQC 2021 Joint Conference

Immune Landscape Signatures for Characterization of Tumor Microenvironment and Response to Therapy

Gene expression and analysis for detection of 38 Immune Landscape Signatures

Using Gene Signature Methodologies to Strengthen Immuno-Oncology Trials

Genomic technologies that empower and enhance immuno-oncology trials

Laboratory Solutions for Hepatitis B (HBV) Clinical Trials

Insight brief by Joseph Sebastian, Ph.D., Scientific Advisor, Infectious & Liver Diseases

Enabling blood sample prep for single cell sequencing in clinical research

The Role of Genomics in Clinical Trials with Patrick Hurban

I-O clinical development podcast series

IQVIA Laboratories Corporate Brochure

Learn about what we do and our commitment to innovation

Evaluating and Implementing SARS-CoV-2 PCR Tests for Diagnostic and Clinical Trial Use

AAPS 2020 COVID-19 Workshop: Current Pharmaceutical Developments for Cures and Prevention

See All